NorthWest Biotherapeutics Inc (NWBO)

[Red_Right_Hand]

Parliament and the MHRA say otherwise

https://questions-statements.parliament.uk/written-questions/detail/2025-11-13/hl11920
Northwest Biotherapeutics has submitted a Marketing Authorization Application to the MHRA for DCVax®-L, an immunotherapy for glioblastoma. The MHRA is unable to comment on applications during the process of review, but the MHRA can confirm that this application is not affected by any historical backlogs, and the agency is assessing all applications rapidly for safety, quality, and efficacy.

https://questions-statements.parliament.uk/written-questions/detail/2025-11-11/89869
Northwest Biotherapeutics has submitted a Marketing Authorization Application (MAA) to the MHRA for DCVax®-L, an immunotherapy for glioblastoma. The MHRA are unable to comment on applications during the process of review, but the MHRA can confirm that this application is not affected by any backlogs.

https://questions-statements.parliament.uk/written-questions/detail/2025-04-17/45872
Northwest Biotherapeutics has submitted a Marketing Authorization Application to the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) for DCVax-L, an immunotherapy for glioblastoma. The MHRA is working with the applicant to reach a decision on this application, to ensure a thorough review that ensures quality, safety, and efficacy.

https://questions-statements.parliament.uk/written-questions/detail/2025-12-02/96433
Northwest Biotherapeutics has submitted a Marketing Authorisation Application to the Medicines and Healthcare products Regulatory Agency (MHRA) for DCVax-L, an immunotherapy for glioblastoma. The MHRA is unable to comment on applications during the process of review, but the MHRA can confirm that this application is not affected by any historical backlogs and is assessing all applications rapidly for safety, quality, and efficacy.